Exposure of Intestinal Epithelial Cells to 2'-Fucosyllactose and CpG Enhances Galectin Release and Instructs Dendritic Cells to Drive Th1 and Regulatory-Type Immune Development.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
19 05 2020
Historique:
received: 25 04 2020
accepted: 15 05 2020
entrez: 23 5 2020
pubmed: 23 5 2020
medline: 7 4 2021
Statut: epublish

Résumé

Intestinal epithelial cells (IEC) release immunomodulatory galectins upon exposure to CpG DNA (mimicking bacterial triggers) and short-chain galacto- and long-chain fructo-oligosaccharides (GF). This study aims to investigate the immunomodulatory properties of 2'-fucosyllactose (2'-FL), a non-digestible oligosaccharide (NDO) abundantly present in human milk, using a co-culture model developed to study the crosstalk between IEC and innate and adaptive immune cells. IECs, co-cultured with αCD3/CD28-activated peripheral blood mononuclear cells (PBMC), were apically exposed to NDOs and CpG, washed and co-cultured with immature monocyte-derived dendritic cells (moDC). Subsequently, moDC were co-cultured with naïve CD4+ T-cells. In the presence of CpG, both 2'-FL or GF-exposed IEC enhanced Th1-type IFNγ and regulatory IL-10 secretion of PBMCs, compared to CpG alone, while Th2-type IL-13 was reduced. Both NDOs increased IEC-derived galectin-3, -4, -9 and TGF-β1 of CpG-exposed IEC. Only galectin-9 correlated with all modified immune parameters and TGF-β1 secretion. MoDCs exposed to 2'-FL and CpG-conditioned IEC instructed IFNγ and IL-10 secretion by CD4+ T-cells, suggesting the development of a regulatory Th1 response. These results reveal that 2'-FL and GF could contribute to the mucosal immune development by supporting the effect of microbial CpG DNA associated with the modulation of epithelial galectin and TGF-β1 secretion.

Identifiants

pubmed: 32438601
pii: biom10050784
doi: 10.3390/biom10050784
pmc: PMC7278199
pii:
doi:

Substances chimiques

CPG-oligonucleotide 0
Culture Media, Conditioned 0
Galectins 0
Oligodeoxyribonucleotides 0
Transforming Growth Factor beta 0
Trisaccharides 0
Interleukin-10 130068-27-8
Interferon-gamma 82115-62-6
2'-fucosyllactose XO2533XO8R

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Mol Med (Berl). 2016 May;94(5):545-56
pubmed: 26631140
J Leukoc Biol. 2017 Jul;102(1):105-115
pubmed: 28495789
Front Immunol. 2018 May 11;9:923
pubmed: 29867934
Nutr Rev. 2013 Dec;71(12):773-89
pubmed: 24246032
Clin Immunol. 2008 Apr;127(1):78-88
pubmed: 18282810
Int Immunol. 2019 Feb 6;31(1):13-21
pubmed: 30281080
Br J Nutr. 2010 Nov;104(9):1261-71
pubmed: 20522272
Biochem Soc Trans. 2008 Dec;36(Pt 6):1472-7
pubmed: 19021578
Anat Sci Int. 2017 Jan;92(1):25-36
pubmed: 27590897
Biochim Biophys Acta. 2002 Sep 19;1572(2-3):232-54
pubmed: 12223272
Allergy. 2012 Mar;67(3):343-52
pubmed: 22229637
J Innate Immun. 2013;5(6):625-38
pubmed: 23735749
Nat Rev Immunol. 2014 Mar;14(3):141-53
pubmed: 24566914
J Food Sci. 2018 Feb;83(2):499-508
pubmed: 29377120
Pediatr Res. 2004 Oct;56(4):536-40
pubmed: 15295093
PLoS One. 2013 Jul 05;8(7):e68367
pubmed: 23861894
Nat Rev Immunol. 2009 May;9(5):338-52
pubmed: 19365409
Sci Rep. 2017 May 03;7:46790
pubmed: 28467395
Immunity. 2014 Aug 21;41(2):270-82
pubmed: 25065622
PLoS One. 2014 Jul 07;9(7):e101692
pubmed: 24999728
Int Arch Allergy Immunol. 2010;152(2):159-68
pubmed: 20016198
Clin Immunol. 2014 Oct;154(2):91-9
pubmed: 25058467
Exp Biol Med (Maywood). 2017 Oct;242(16):1633-1642
pubmed: 28534432
PLoS One. 2008 Jul 09;3(7):e2629
pubmed: 18612433
J Gastroenterol. 2017 Jul;52(7):777-787
pubmed: 28534191
J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):296-301
pubmed: 28114245
Mol Med Rep. 2013 Jan;7(1):205-10
pubmed: 23064791
Gut. 2016 Jan;65(1):33-46
pubmed: 25431457
Nutr Rev. 2017 Nov 1;75(11):920-933
pubmed: 29053807
Clin Transl Immunology. 2017 Apr 07;6(4):e136
pubmed: 28523126
Front Pediatr. 2018 Sep 10;6:239
pubmed: 30250836
Eur J Pharmacol. 2011 Sep;668 Suppl 1:S124-32
pubmed: 21816141
Mediators Inflamm. 2019 Jul 25;2019:8456829
pubmed: 31427886
Front Immunol. 2018 Mar 09;9:452
pubmed: 29593719
Nat Rev Immunol. 2018 Jun;18(6):405-415
pubmed: 29491358
Nat Rev Immunol. 2003 Apr;3(4):331-41
pubmed: 12669023
J Nutr. 2016 Dec;146(12):2559-2566
pubmed: 27798337
Immunobiology. 2011 Apr;216(4):518-27
pubmed: 20850889
Dig Dis Sci. 2002 Oct;47(10):2316-24
pubmed: 12395905
Int J Biomed Sci. 2006 Jun;2(2):114-20
pubmed: 23674973
J Innate Immun. 2017;9(6):609-620
pubmed: 28889122
Front Immunol. 2019 Jul 31;10:1773
pubmed: 31417553

Auteurs

Veronica Ayechu-Muruzabal (V)

Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 Utrecht, The Netherlands.

Saskia A Overbeek (SA)

Global Centre of Excellence in Immunology, Danone Nutricia Research B.V., 3584 CT Utrecht, The Netherlands.

Atanaska I Kostadinova (AI)

Global Centre of Excellence in Immunology, Danone Nutricia Research B.V., 3584 CT Utrecht, The Netherlands.

Bernd Stahl (B)

Global Centre of Excellence in Human Milk Research & Analytical Sciences, Danone Nutricia Research B.V., 3584 CT Utrecht, The Netherlands.
Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.

Johan Garssen (J)

Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 Utrecht, The Netherlands.
Global Centre of Excellence in Immunology, Danone Nutricia Research B.V., 3584 CT Utrecht, The Netherlands.

Belinda Van't Land (B)

Global Centre of Excellence in Immunology, Danone Nutricia Research B.V., 3584 CT Utrecht, The Netherlands.
Center for Translational Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, 3584 EA Utrecht, The Netherlands.

Linette E M Willemsen (LEM)

Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH